Xenetic Bioscience

Xenetic Biosciences, Inc. is a biopharmaceutical company headquartered in Framingham, Massachusetts, specializing in the development of innovative cancer therapies and drug delivery solutions. The company focuses on advancing its XCART platform, a personalized chimeric antigen receptor T cell technology designed to target patient-specific tumor neoantigens and treat B-cell lymphomas. Additionally, Xenetic is developing its DNase platform to enhance the efficacy of existing cancer treatments by targeting neutrophil extracellular traps, which are linked to cancer progression and treatment resistance. The company also has an investigational drug candidate, XBIO-101, aimed at treating progestin-resistant endometrial cancer. Through collaborations with major pharmaceutical organizations, Xenetic Biosciences leverages its proprietary PolyXen drug delivery technology to improve the performance of various drugs and vaccines across critical medical areas, including oncology.

Michael Scott Maguire

CEO and Chairman

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.